Drivers of prognosis and clinical trajectories differ between COVID and non-COVID acute hypoxic respiratory failure
Patients with AHRF from COVID had fewer non-respiratory comorbidities or goals of care limitations, more prolonged respiratory failure and higher risk of mortality related to hypoxemia. These differences could explain why patients with COVID AHRF may experience greater benefit from disease-specific therapies targeting AHRF compared to patients with non-COVID AHRF.
Authors
- Haley Morin (ORCID: https://orcid.org/0000-0003-1967-7890)
- William Collins (ORCID: https://orcid.org/0000-0003-0974-2599)
- Jennifer Wilson (ORCID: https://orcid.org/0000-0002-1598-3471)
- Katie M. Lebold
- Pablo Sanchez (ORCID: https://orcid.org/0000-0002-6324-5086)
- Tara Ramaswamy (ORCID: https://orcid.org/0000-0003-1504-1721)
- Alexandria M. Jensen (ORCID: https://orcid.org/0000-0001-6337-9079)
- Jonasel Roque
- Caitlin M. Parmer (ORCID: https://orcid.org/0000-0003-0770-2286)
- Joseph E. Levitt (ORCID: https://orcid.org/0000-0001-5316-4971)
- Christian O’Donnell (ORCID: https://orcid.org/0000-0002-4243-243X)
- S. Pienkos
- Andrew R. Moore
- Ana Pacheco-Navarro
- Angela J. Rogers
Institutions
- Oregon Health & Science University (US)
- Stanford Health Care (US)
- Stanford Medicine (US)
- Stanford University (US)
Publication Details
- Journal
- PLoS ONE
- Published
- 2025-12-26
- DOI
- https://doi.org/10.1371/journal.pone.0339604
- Primary Topic
- Respiratory Support and Mechanisms
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Heart, Lung, and Blood Institute